Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03744312 · ClinicalTrials.gov registry record · Phase 1

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

A Phase 1 study of Alzheimer Disease, sponsored by Columbia University.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT03744312 is a Phase 1 study of Alzheimer Disease that has completed, run by Columbia University. The registered enrollment target is 9 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03744312, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI) or Alzheimer's disease) and healthy controls (participants without memory complaints or impairment) will be included in this study.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG 11C-ER176
  • DRUG Florbetaben

Study Locations (1)

New York

  • Columbia University Irving Medical Center - New York

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2018-09-10
Est. Completion 2022-07-20
Phase Phase 1

Sponsor

Columbia University

958 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03744312

The ClinicalTrials.gov registry entry for NCT03744312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which 11C-ER176 is the first listed.

NCT03744312 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03744312 about?

NCT03744312 is a clinical study titled "Imaging Inflammation in Alzheimer's Disease With 11C-ER176". This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI)...

What is the current status of trial NCT03744312?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-09-10. Estimated completion is 2022-07-20.

What conditions does trial NCT03744312 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT03744312?

The interventions under investigation include: 11C-ER176 (DRUG), Florbetaben (DRUG).

Who is sponsoring clinical trial NCT03744312?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03744312 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.